“the Company is building brands that will be key drivers for value creation”
	Mr. Harish Narula President Corporate Development & CIS

The growing CIS pharmaceutical market with an estimated size of USD 17 billion represents a great opportunity. An ageing population, changing lifestyles, steadily rising incomes and increased Government spending in health-care are all indicators that back Lupin's decision to expand its presence in this region. In particular, Russia and Ukraine are of prime interest. Lupin's presence in the region is marked by both a Direct-to-Market as well as a Local Partnership strategy. Local partnerships have been established keeping in mind their future potential and cross-functional synergies.

The CIS business has been built around offering differentiated products with a long term view of creating strong niches from product mix, comprising Value Added Generics, Branded Generics and the Company's Branded Business. Bearing in mind changing market dynamics, Lupin is putting added emphasis on brand building exercises for its products such as IXIME, Dr. KASHEL, SOFTOVAC, RIBAVIN, ONE-BE and GATISPAN. The Company's Branded Business recorded a healthy growth rate and brands such as IXIME and Dr. KASHEL are fast gaining market share.

Lupin plans to continue the strengthening of its presence in the CIS region by filing the right products, increasing its field force, forging strategic trade relationships and enhancing its distributor networks. The Company is looking forward to building new brands from its filings in the region, which shall be key drivers for value creation in the years to come.